Key Insights

• Alterity Therapeutics' Annual General Meeting to take place on 28th of November

• CEO David Stamler's total compensation includes salary of AU$731.4k

• The overall pay is 183% above the industry average

• Over the past three years, Alterity Therapeutics' EPS grew by 41% and over the past three years, the total loss to shareholders 88%

The underwhelming share price performance of Alterity Therapeutics Limited (ASX:ATH) in the past three years would have disappointed many shareholders. However, what is unusual is that EPS growth has been positive, suggesting that the share price has diverged from fundamentals. Shareholders may want to question the board on the future direction of the company at the upcoming AGM on 28th of November. They could also try to influence management and firm direction through voting on resolutions such as executive remuneration and other company matters. Here's our take on why we think shareholders may want to be cautious of approving a raise for the CEO at the moment.

View our latest analysis for Alterity Therapeutics

Comparing Alterity Therapeutics Limited's CEO Compensation With The Industry

At the time of writing, our data shows that Alterity Therapeutics Limited has a market capitalization of AU$9.8m, and reported total annual CEO compensation of AU$1.6m for the year to June 2023. That is, the compensation was roughly the same as last year. While this analysis focuses on total compensation, it's worth acknowledging that the salary portion is lower, valued at AU$731k.

For comparison, other companies in the Australian Biotechs industry with market capitalizations below AU$305m, reported a median total CEO compensation of AU$583k. This suggests that David Stamler is paid more than the median for the industry.

On an industry level, around 60% of total compensation represents salary and 40% is other remuneration. It's interesting to note that Alterity Therapeutics allocates a smaller portion of compensation to salary in comparison to the broader industry. If non-salary compensation dominates total pay, it's an indicator that the executive's salary is tied to company performance.

Alterity Therapeutics Limited's Growth

Alterity Therapeutics Limited has seen its earnings per share (EPS) increase by 41% a year over the past three years. Its revenue is down 24% over the previous year.

Overall this is a positive result for shareholders, showing that the company has improved in recent years. It's always a tough situation when revenues are not growing, but ultimately profits are more important. Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts.